Hologic, Inc. (NASDAQ:HOLX) VP Karleen Marie Oberton sold 4,704 shares of the company’s stock in a transaction dated Monday, July 17th. The shares were sold at an average price of $45.19, for a total value of $212,573.76. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.

Shares of Hologic, Inc. (NASDAQ:HOLX) traded up 0.73% on Wednesday, reaching $45.28. The company’s stock had a trading volume of 2,259,133 shares. The company’s 50 day moving average price is $44.96 and its 200 day moving average price is $42.66. The company has a market cap of $12.68 billion, a P/E ratio of 16.24 and a beta of 0.91. Hologic, Inc. has a 12-month low of $35.15 and a 12-month high of $46.80.

Hologic (NASDAQ:HOLX) last issued its quarterly earnings results on Wednesday, May 10th. The medical equipment provider reported $0.50 EPS for the quarter, topping analysts’ consensus estimates of $0.46 by $0.04. Hologic had a return on equity of 25.26% and a net margin of 27.31%. The firm had revenue of $715.40 million for the quarter, compared to analysts’ expectations of $685.24 million. During the same period in the previous year, the firm posted $0.47 EPS. The business’s revenue for the quarter was up 3.2% compared to the same quarter last year. Analysts forecast that Hologic, Inc. will post $2.01 EPS for the current fiscal year.

COPYRIGHT VIOLATION NOTICE: This article was first reported by American Banking News and is owned by of American Banking News. If you are reading this article on another site, it was illegally stolen and reposted in violation of U.S. and international copyright legislation. The original version of this article can be viewed at https://www.americanbankingnews.com/2017/07/19/hologic-inc-nasdaqholx-vp-sells-212573-76-in-stock.html.

Several brokerages recently commented on HOLX. Barclays PLC restated an “overweight” rating and set a $53.00 target price (up previously from $50.00) on shares of Hologic in a research report on Monday. Piper Jaffray Companies restated a “buy” rating and set a $51.00 target price on shares of Hologic in a research report on Friday, July 14th. Stifel Nicolaus restated a “buy” rating on shares of Hologic in a research report on Friday, July 14th. Zacks Investment Research lowered Hologic from a “hold” rating to a “sell” rating in a research report on Wednesday, July 12th. Finally, Jefferies Group LLC restated a “buy” rating and set a $49.00 target price on shares of Hologic in a research report on Wednesday, June 28th. One analyst has rated the stock with a sell rating, four have issued a hold rating and nine have assigned a buy rating to the stock. Hologic presently has an average rating of “Buy” and a consensus price target of $47.77.

Several hedge funds have recently modified their holdings of the company. Cleararc Capital Inc. boosted its position in Hologic by 1.1% in the first quarter. Cleararc Capital Inc. now owns 6,843 shares of the medical equipment provider’s stock valued at $291,000 after buying an additional 77 shares during the period. Compton Capital Management Inc. RI boosted its position in Hologic by 0.6% in the first quarter. Compton Capital Management Inc. RI now owns 16,810 shares of the medical equipment provider’s stock valued at $715,000 after buying an additional 100 shares during the period. Advantus Capital Management Inc boosted its position in Hologic by 0.4% in the first quarter. Advantus Capital Management Inc now owns 27,936 shares of the medical equipment provider’s stock valued at $1,189,000 after buying an additional 116 shares during the period. Shell Asset Management Co. boosted its position in Hologic by 0.7% in the first quarter. Shell Asset Management Co. now owns 24,647 shares of the medical equipment provider’s stock valued at $1,049,000 after buying an additional 182 shares during the period. Finally, Curbstone Financial Management Corp boosted its position in Hologic by 2.4% in the second quarter. Curbstone Financial Management Corp now owns 8,678 shares of the medical equipment provider’s stock valued at $394,000 after buying an additional 200 shares during the period. 94.04% of the stock is currently owned by hedge funds and other institutional investors.

Hologic Company Profile

Hologic, Inc is a developer, manufacturer and supplier of diagnostics products, medical imaging systems and surgical products with an emphasis on women’s health. The Company operates through four segments: Diagnostics, Breast Health, GYN Surgical and Skeletal Health. The diagnostics products include Aptima family of assays, ThinPrep system, the Rapid Fetal Fibronectin Test and Procleix blood screening assays.

Insider Buying and Selling by Quarter for Hologic (NASDAQ:HOLX)

Receive News & Ratings for Hologic Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hologic Inc. and related companies with MarketBeat.com's FREE daily email newsletter.